Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
IPO
2026 World Cup
Rewards
Square
Latest
Hot
News
Profile

Cinda Biotech (01801.HK) rises more than 7% after reaching an exclusive licensing agreement with Spero Therapeutics for IBI355

GasGuzzler
robot
Abstract generation in progress
Cinda Biotech (01801.HK) +7.650 (+8.495%) shorted $317 million; ratio 26.693%. Today (15th) opened 3.83% higher, with a high of 96.75. The latest is 96.75, up 7.44%, with 7.8256 million shares traded, involving $740 million. Cinda Biotech and Spero Therapeutics have reached an exclusive licensing agreement for IBI355 (third-generation anti-CD40L monoclonal antibody, in the clinical Phase II preparation stage). Under the terms of the agreement, Spero will obtain global exclusive development, research, manufacturing and commercialization rights for IBI355 (Spero R&D code: SP001) outside the Greater China region. Related content 《Big bank》: Lyon upgrades Cinda Biotech (01801.HK) target price to 111.4. Interim results beat expectations. Cinda Biotech will receive an upfront payment and is also eligible to receive development, registration and commercialization potential milestone payments, with total deal value of approximately $1.1 billion; it will also receive tiered sales royalties based on the product’s future net sales. Spero plans to initiate a Phase II clinical study of IBI355 for IgG4-related diseases (IgG4-RD) in the second quarter of 2027. IgG4-RD is a severe, chronic inflammatory disease with fibrosis, with a heavy treatment burden and limited treatment options. Cinda Biotech plans to launch a Phase II clinical study of IBI355 for Sjögren’s syndrome (SjD) in China before early 2027. SjD is a chronic autoimmune disease with limited treatment options. (ad/da)(Hong Kong stock quotes delayed by at least fifteen minutes. Short-selling data as of 2026-07-14 16:25.)
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments

  • Pinned

Sitemap